Tower Research Capital LLC TRC Acquires 3,538 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Tower Research Capital LLC TRC boosted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 319.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,646 shares of the medical instruments supplier's stock after buying an additional 3,538 shares during the quarter. Tower Research Capital LLC TRC's holdings in LeMaitre Vascular were worth $428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its stake in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC lifted its position in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 117 shares in the last quarter. KBC Group NV raised its stake in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after acquiring an additional 410 shares during the period. Huntington National Bank boosted its holdings in LeMaitre Vascular by 64.9% during the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after acquiring an additional 455 shares during the period. Finally, Empowered Funds LLC purchased a new stake in LeMaitre Vascular during the 4th quarter worth approximately $150,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

Insider Activity at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.79% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LMAT shares. Lake Street Capital upped their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $98.14.

LeMaitre Vascular Trading Down 12.8 %

Shares of LMAT traded down $11.54 during trading hours on Friday, hitting $78.70. 601,984 shares of the stock traded hands, compared to its average volume of 162,901. The business has a fifty day moving average of $85.58 and a 200-day moving average of $93.34. The firm has a market capitalization of $1.78 billion, a PE ratio of 43.01, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 earnings per share. As a group, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date is Thursday, May 15th. LeMaitre Vascular's dividend payout ratio is 41.24%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.